Portfolio Sync Solutions
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTEDSonnet BioTherapeutics Holdings, Inc. Analyst EPS Estimates
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|---|---|---|---|
| Q1 2024 | 1 | -$5.60 | -$5.60 | -$5.60 |
| Q2 2024 | 1 | -$6.12 | -$6.12 | -$6.12 |
| Q3 2024 | 1 | -$5.52 | -$5.52 | -$5.52 |
| Q4 2024 | 1 | -$4.16 | -$4.16 | -$4.16 |
| Q1 2025 | 1 | -$4.08 | -$4.08 | -$4.08 |
| Q2 2025 | 1 | -$3.36 | -$3.36 | -$3.36 |
| Q3 2025 | 1 | -$3.36 | -$3.36 | -$3.36 |
Sonnet BioTherapeutics Holdings, Inc. Earnings Date And Information
Sonnet BioTherapeutics Holdings, Inc. last posted its earnings results on Wednesday, August 14th, 2024. The company reported $-5.6 earnings per share for the quarter, missing analysts' consensus estimates of $-0.76 by $4.84. The company had revenue of 9.08 M for the quarter and had revenue of 18,626 for the year. Sonnet BioTherapeutics Holdings, Inc. has generated $-11 earnings per share over the last year ($-11.35 diluted earnings per share) and currently has a price-to-earnings ratio of -0.2. Sonnet BioTherapeutics Holdings, Inc. has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, February 12th, 2025 based on prior year's report dates.
Sonnet BioTherapeutics Holdings, Inc. Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
|---|---|---|---|---|---|---|
| 12/17/2024 | Q4 2024 | -$3.33 | $28,000 | $9.08 M | ||
| 08/14/2024 | Q3 2024 | -$0.76 | -$0.70 | 0.06 | $28,500 | $0 |
| 05/14/2024 | Q2 2024 | $0.14 | $0.08 | -0.06 | $0 | |
| 02/14/2024 | Q1 2024 | -$0.90 | -$0.31 | 0.59 | $18,626 | |
| 12/14/2023 | Q4 2023 | -$2.09 | $31,100 | $37,255 | ||
| 08/14/2023 | Q3 2023 | -$0.31 | -$2.96 | -2.65 | $20,000 | $36,850 |
| 05/10/2023 | Q2 2023 | -$0.49 | -$7.56 | -7.07 | $36,445 | |
| 02/13/2023 | Q1 2023 | -$1.10 | -$17.40 | -16.3 | $37,255 | |
| 12/15/2022 | Q4 2022 | -$1.51 | -$37.19 | -35.68 | $100,000 | $62,753 |
| 08/15/2022 | Q3 2022 | -$1.96 | -$40.07 | -38.11 | $50,000 | $62,071 |
| 05/10/2022 | Q2 2022 | -$1.68 | -$41.92 | -40.24 | $95,320 | |
| 02/08/2022 | Q1 2022 | -$92.34 | -$31.53 | 60.81 | $129,799 | |
| 12/16/2021 | Q4 2021 | -$3.08 | -$53.88 | -50.8 | $483,626 | |
| 08/16/2021 | Q3 2021 | -$83.71 | $0 | |||
| 05/17/2021 | Q2 2021 | -$99.24 | $0 | |||
| 02/16/2021 | Q1 2021 | -$105.13 | $0 | |||
| 12/17/2020 | Q4 2020 | -$153.11 | $12.74 M | $-5,681,238 | ||
| 08/14/2020 | Q3 2020 | -$322.10 | $12.73 M | $0 | ||
| 05/18/2020 | Q2 2020 | -$103.47 | $5.68 M | |||
| 03/18/2020 | Q1 2020 | -$136.00 | $0 |
Sonnet BioTherapeutics Holdings, Inc. Earnings: FAQ's
When is Sonnet BioTherapeutics Holdings, Inc.'s earnings date?
Sonnet BioTherapeutics Holdings, Inc. has not confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, February 12th, 2025 based off last year's report dates.
How can I listen to Sonnet BioTherapeutics Holdings, Inc.'s earnings conference
call?
The conference call for Sonnet BioTherapeutics Holdings, Inc.'s latest earnings report can be listened to online.
How can I read Sonnet BioTherapeutics Holdings, Inc.'s conference call transcript?
The conference call transcript for Sonnet BioTherapeutics Holdings, Inc.'s latest earnings report can be read online.
How much revenue does Sonnet BioTherapeutics Holdings, Inc. generate each year?
Sonnet BioTherapeutics Holdings, Inc. (:SONN) has a recorded annual revenue of $18,626.
How much profit does Sonnet BioTherapeutics Holdings, Inc. generate each year?
Sonnet BioTherapeutics Holdings, Inc. (:SONN) has a recorded net income of $18,626. Sonnet BioTherapeutics Holdings, Inc. has generated $-11.35 earnings per share over the last four quarters.
What is Sonnet BioTherapeutics Holdings, Inc.'s price-to-earnings ratio?
Sonnet BioTherapeutics Holdings, Inc. (:SONN) has a price-to-earnings ratio of -0.2 and price/earnings-to-growth ratio is 0.